循环miRNA在绝经后骨质疏松女性地舒单抗治疗2年后有应答——MiDeTe研究
这项前瞻性、观察性、单中心研究纳入21例接受地舒单抗(DMAB)治疗的绝经后骨质疏松女性,随访2年。治疗2年后髋部骨密度(BMD)增加5.5%(P=0.0006)、腰椎BMD增加11.4%(P=0.017),CTX降低64.1%(P<0.0001)、P1NP降低69.3%(P<0.0001);7种miRNA显著上调,其中4种主要在单核细胞等血细胞中转录,miRNA变化与BTM变化及BMD变化相关,miR-454-3p、miR-26b-5p和miR-584-5p被定义为最有希望的生物标志物候选。
要点
- 地舒单抗治疗2年后髋部BMD增加5.5%、腰椎BMD增加11.4%,CTX降低64.1%、P1NP降低69.3%。
- 治疗2年后7种循环miRNA较基线显著变化,其中4种主要在单核细胞等血细胞中转录。
- miR-454-3p、miR-26b-5p、miR-584-5p被定义为与地舒单抗持续骨效应关联最强的候选生物标志物。
核心结论
- 2年地舒单抗治疗导致7种miRNA上调,其中4种主要在单核细胞中转录,提示地舒单抗可能影响循环破骨前体细胞。
- 这些miRNA变化与BMD增加和骨转换标志物抑制相关,可能有助于监测地舒单抗治疗应答。
研究设计与样本
- 前瞻性、观察性、单中心研究,纳入21例接受地舒单抗治疗的绝经后骨质疏松女性,纵向随访2年。
- 在基线、第6个月和第24个月采用下一代测序(NGS)筛查血清miRNA,并用逆转录定量聚合酶链反应(RT-qPCR)在全队列中确认NGS结果。
- 评估骨转换标志物P1NP和CTX,以及双能X线吸收法测定的骨密度(BMD),并与miRNA进行相关性分析。
主要发现
- 治疗期间髋部BMD增加5.5%(P=0.0006),腰椎BMD增加11.4%(P=0.017)。
- 治疗期间CTX降低64.1%(P<0.0001),P1NP降低69.3%(P<0.0001)。
- NGS分析显示地舒单抗治疗2年后miRNA出现显著变化,但治疗6个月后未出现显著变化。
- RT-qPCR确认7种miRNA在2年地舒单抗治疗过程中较基线显著变化,其中4种主要在血细胞(包括单核细胞)中转录。
- 相关性分析发现miRNA变化与BTM变化及BMD变化之间存在显著相关。
关键数值与推荐
- 基于效应量和相关强度,miR-454-3p、miR-26b-5p和miR-584-5p被定义为最重要的生物标志物候选,与地舒单抗对骨质疏松患者骨的持续效应关联最强。
临床怎么用
- 原文结论指出,循环miRNA变化与BMD增加和BTM抑制相关,可能有助于监测地舒单抗治疗应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: MicroRNAs (miRNAs)-short, single-stranded, noncoding RNAs-regulate several biological processes, including bone metabolism. OBJECTIVE: We investigated circulating miRNAs as promising biomarkers for treatment monitoring in women with postmenopausal osteoporosis on denosumab (DMAB) therapy. METHODS: In this prospective, observational, single-center study, 21 postmenopausal women treated with DMAB were included for a longitudinal follow-up of 2 years. Next-generation sequencing (NGS) was performed to screen for serological miRNAs at baseline, month 6, and month 24. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to confirm NGS findings in the entire cohort. Bone turnover markers (BTM) P1NP and CTX, and bone mineral density (BMD) by dual x-ray absorptiometry were assessed and correlated to miRNAs. RESULTS: BMD at the hip (5.5%, P = 0.0006) and lumbar spine significantly increased (11.4%, P = 0.017), and CTX (64.1%, P < 0.0001) and P1NP (69.3%, P < 0.0001) significantly decreased during treatment. NGS analysis revealed significant changes in miRNAs after 2 years of DMAB treatment but not after 6 months. Seven miRNAs were confirmed by RT-qPCR to be significantly changed during a 2-year course of DMAB treatment compared to baseline. Four of these were mainly transcribed in blood cells, including monocytes. Correlation analysis identified significant correlation between change in miRNA and change in BTMs as well as BMD. Based on effect size and correlation strength, miR-454-3p, miR-26b-5p, and miR-584-5p were defined as top biomarker candidates, with the strongest association to the sustained effect of denosumab on bone in osteoporotic patients. CONCLUSION: Two years of DMAB treatment resulted in upregulation of 7 miRNAs, 4 of which are mainly transcribed in monocytes, indicating a potential impact of DMAB on circulating osteoclast precursor cells. These changes were associated to BMD gain and BTM suppression and could therefore be useful for monitoring DMAB treatment response.
引用
- Messner Z, Carro Vázquez D, Haschka J, et al. Circulating miRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis-the MiDeTe study. J Clin Endocrinol Metab. 2023. PMID: 36408612. doi:10.1210/clinem/dgac667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。